Is Rivaroxaban CYP3A4?

Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporter. Rivaroxaban is metabolized by the CYP3A4 metabolizing enzyme. CYP3A4 is an enzyme system widely present in the liver and participates in the metabolism of many drugs. Rivaroxaban is metabolized by CYP3A4 into multiple active metabolites in the body. When used concomitantly with other drugs, drug interactions may occur, causing the metabolism of rivaroxaban to be affected. Coadministration of P-gp and strong CYP3A inhibitors increases rivaroxaban exposure and may increase the risk of bleeding. Coadministration of P-gp and strong CYP3A inducers may reduce rivaroxaban exposure and may increase the risk of thromboembolic events.